News

Legend Biotech Showcases Groundbreaking Findings at ASH Event

Legend Biotech Showcases Groundbreaking Findings at ASH Event

Legend Biotech's Key Presentations at the ASH Annual Meeting

Legend Biotech Corporation (NASDAQ: LEGN), a pioneer in cell therapy, is excited to announce a series of transformative presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting. With two oral presentations and seven poster presentations focused on their leading CAR-T therapy, CARVYKTI®, our presentations underscore the ongoing commitment to advancing treatment options for multiple myeloma.

Highlights from the Presentations

The upcoming ASH meeting, taking place from December 6-9, 2025, is set to feature groundbreaking data from our research. Among the highlights is a first-in-human Phase 1 study on Lucar-G39D, an allogeneic CAR-T cell therapy targeting relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) that will be discussed in an oral session. “Our presentations this year demonstrate the depth and innovation in our therapy programs,” remarked Ying Huang, Ph.D., CEO of Legend Biotech.

CARVYKTI: BCA-Targeted Innovation

CARVYKTI is renowned as the first BCMA-targeted CAR-T cell therapy approved for patients who’ve undergone at least one prior line of treatment for multiple myeloma. To date, it has been administered to over 9,000 patients across 14 countries, showcasing its growing global impact.

Key Abstracts at ASH

This year, nine abstracts are spotlighting CARVYKTI, focusing on its durability, evolving safety profile, and real-world outcomes—reiterating its pivotal role in the treatment pathway for multiple myeloma.

Notable Abstracts and Presentations

One of the standout oral presentations is titled “Long-Term Progression-Free Survival Benefit With Ciltacabtagene Autoleucel in Standard-Risk Relapsed/Refractory Multiple Myeloma,” scheduled for December 6. This presentation will explore the potential long-term benefits of early intervention with CARVYKTI in clinical settings.

Additionally, the abstract “Earlier Use of Ciltacabtagene Autoleucel (Cilta-cel) Is Associated With Better Immune Fitness” further supports the concept of timely treatments to optimize patient outcomes through correlative analyses from the CARTITUDE-4 study.

Investigation of Other Therapies

The event will also feature a detailed analysis of Lucar-G39D, discussing its dual-target capabilities against CD20 and CD19 in patients with NHL. This represents our ongoing dedication to pioneering next-generation treatments that may redefine care standards in hematological malignancies.

Ongoing Commitment to Safety

While exploring these groundbreaking findings, patient safety remains a top priority. A section of our presentations will address CARVYKTI’s important safety information, including warnings around cytokine release syndrome and neurological toxicities. We ensure that patients and healthcare providers are well-informed about the benefits and potential risks involved with novel therapies.

About Legend Biotech

With a workforce of over 2,800 dedicated professionals, Legend Biotech is the largest standalone cell therapy company, driving innovations in cancer treatment, particularly through CARVYKTI. Collaborating with Johnson & Johnson, Legend Biotech is committed to broadening access and maximizing patient care across its therapeutic platforms.

Frequently Asked Questions

What is the significance of CARVYKTI in cancer treatment?

CARVYKTI is the first approved BCMA-targeted CAR-T therapy for multiple myeloma, offering significant treatment options for patients after previous therapies.

When and where will the ASH Annual Meeting take place?

The Annual Meeting is scheduled for December 6-9, 2025, with presentations made in Orlando.

What are some topics discussed in the presentations?

Key presentation topics include survival benefits and immune response to Ciltacabtagene Autoleucel, and innovations in next-gen therapies targeting NHL.

How does Legend Biotech ensure patient safety?

Legend Biotech emphasizes patient safety through comprehensive risk assessment and management plans surrounding the administration of therapies like CARVYKTI.

What is Legend Biotech's role in the CAR-T therapy market?

As a leader in cell therapy, Legend Biotech focuses on cutting-edge CAR-T therapeutics, pioneering research, and enhancing therapeutic accessibility while championing patient care.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 147

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 124

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 71

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 113

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 54

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 250

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 58

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 126

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 152

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 62

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading

Top 5 Most Recently Viewed Articles

Eimskip's Q3 2025 Financial Overview and Future Outlook

Updated Category News Views 238

Eimskip's Third Quarter Performance Analysis The results for the third quarter of 2025 have presented challenges for Eimskip, as operations did not meet expectations. Revenues showed significant shifts, revealing both obstacles and opportunities in the company's journey. Operational Insights During Q3, Eimskip experienced a slight increase in liner shipping volumes,...

Continue Reading
Market Trends and Insights: The Bullish Moves on Block

Updated Category News Views 88

Examining Recent Bullish Moves on Block Recently, financial institutions have been making significant bullish strides into Block, a company known for its innovative payment services. Analysis of the options trading history for Block (NASDAQ: SQ) indicates a noticeable interest, with 16 unusual trades captured, providing insights into market direction and trader sentiment....

Continue Reading
Exploring the Soaring Online Poker Market Growth Trends

Updated Category News Views 157

Online Poker Market: A Surge on the Horizon The Global Online Poker Market is currently undergoing a transformative expansion, predicted to rise from USD 7.98 billion in 2024 to an impressive USD 37.19 billion by 2030. This notable growth reflects a compound annual growth rate (CAGR) of 29.24%, driven by advancements in technology such as enhanced smartphone capabilities,...

Continue Reading
Elevate Your Gaming with Jackbit's New Crypto Welcome Offer

Updated Category News Views 182

Jackbit’s New Welcome Bonus for Crypto Players As online gaming evolves, Jackbit Crypto Casino is launching an exciting new welcome bonus tailored specifically for cryptocurrency enthusiasts. Starting next year, all new players joining the Jackbit platform will enjoy the same welcome bonuses that traditional fiat customers have been taking advantage of. This bold move...

Continue Reading
Eli Lilly's Mounjaro Drug Set to Revolutionize Weight Loss in Hong Kong

Updated Category News Views 214

Eli Lilly to Launch Weight Loss Drug Mounjaro in Hong Kong Eli Lilly & Co. (NYSE: LLY) is poised to launch its well-regarded weight-loss medication, Mounjaro, in Hong Kong shortly. This marks an exciting milestone, as it positions Mounjaro to be the first of its kind available in the broader region of China. The anticipated launch follows recent reports indicating that...

Continue Reading